Ensign Peak Advisors Inc bought a new stake in Vor Biopharma Inc. (NYSE:VOR – Get Rating) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 209,500 shares of the company’s stock, valued at approximately $834,000. Ensign Peak Advisors Inc owned about 0.54% of Vor Biopharma as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also made changes to their positions in the company. Corton Capital Inc. lifted its position in Vor Biopharma by 37.6% in the second quarter. Corton Capital Inc. now owns 14,856 shares of the company’s stock valued at $74,000 after purchasing an additional 4,061 shares during the period. Delphia USA Inc. purchased a new stake in shares of Vor Biopharma in the second quarter valued at approximately $80,000. Millennium Management LLC grew its holdings in Vor Biopharma by 1,639.3% during the second quarter. Millennium Management LLC now owns 288,942 shares of the company’s stock worth $1,436,000 after acquiring an additional 272,329 shares during the period. Citadel Advisors LLC raised its position in Vor Biopharma by 37.8% in the second quarter. Citadel Advisors LLC now owns 79,374 shares of the company’s stock worth $394,000 after acquiring an additional 21,765 shares in the last quarter. Finally, Bank of Montreal Can purchased a new position in Vor Biopharma in the first quarter worth $283,000.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research note on Monday, February 13th. Oppenheimer dropped their target price on shares of Vor Biopharma from $27.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, November 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Vor Biopharma presently has an average rating of “Moderate Buy” and a consensus price target of $14.83.
Vor Biopharma Price Performance
Vor Biopharma Company Profile
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
- Get a free copy of the StockNews.com research report on Vor Biopharma (VOR)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding VOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vor Biopharma Inc. (NYSE:VOR – Get Rating).
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.